EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Natural killer cell–based immunotherapy for cancer

Shoubao Ma, Jianhua Yu, Michael A Caligiuri

The Journal of Immunology · 01.07.2025 · 214 (7) · 1444-1456

DOI: 10.1093/jimmun/vkaf036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Immunology, online erschienen am 17.04.2025. Verfasst von Shoubao Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, United States. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Immunotherapy, Adoptive, Immunotherapy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are emerging as a promising tool for cancer immunotherapy due to their innate ability to selectively recognize and eliminate cancer cells. Over the past 3 decades, strategies to harness NK cells have included cytokines, small molecules, antibodies, and the adoptive transfer of autologous or allogeneic NK cells, both unmodified and genetically engineered. Despite favorable safety profiles in clinical trials, challenges such as limited in vivo persistence, exhaustion, and the suppressive tumor microenvironment continue to hinder their efficacy and durability. This review categorizes NK cell–based therapies into 3 major approaches: (i) cellular therapies, including unmodified and chimeric antigen receptor–engineered NK cells; (ii) cytokine-based strategies such as interleukin-2 and interleukin-15 derivatives; and (iii) antibody-based therapies, including immune checkpoint inhibitors and NK cell engagers. We highlight these advancements, discuss current limitations, and propose strategies to optimize NK cell–based therapies for improved cancer treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalNeoplasmsImmunotherapy, AdoptiveImmunotherapyHumansAnimalsTumor MicroenvironmentReceptors, Chimeric AntigenImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

CAR NK cellsNK cell engagerscancer immunotherapynatural killer cells

Substanzen

Receptors, Chimeric AntigenImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, United States.
  • Hematologic Malignancies Research Institute, City of Hope National Medical Center, Los Angeles, CA, United States.
  • City of Hope Comprehensive Cancer Center, Los Angeles, CA, United States.
  • Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, United States.
  • Institute for Precision Cancer Therapeutics and Immuno-Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA, United States.
  • Clemons Family Center for Transformative Cancer Research, University of California, Irvine, Irvine, CA, United States.

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • California Institute for Regenerative Medicine
  • NINDS NIH HHS
  • Leukemia and Lymphoma Society
  • National Institutes of Health

Zitieren

APA

Ma, S., Yu, J., & Caligiuri, M. A. (2025). Natural killer cell–based immunotherapy for cancer. The Journal of Immunology, 214(7), 1444-1456. https://doi.org/10.1093/jimmun/vkaf036

Vancouver

Ma S, Yu J, Caligiuri MA. Natural killer cell–based immunotherapy for cancer. The Journal of Immunology. 2025;214(7):1444-1456. doi:10.1093/jimmun/vkaf036

BibTeX
@article{Ma2025,
  author = {Ma, Shoubao and Yu, Jianhua and Caligiuri, Michael A},
  title = {Natural killer cell–based immunotherapy for cancer},
  journal = {The Journal of Immunology},
  year = {2025},
  volume = {214},
  number = {7},
  pages = {1444--1456},
  doi = {10.1093/jimmun/vkaf036}
}
Kostenlos starten →